SCHEMBL23218076

SCHEMBL23218076

CCOC(=O)Cc1ccccc1OCc1cccc2oc(-c3ccnc(CN)c3OC)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.42
CFD P00746 3/20 0.42
TBXAS1 P24557 1/20 0.38
PTK2 Q05397 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ALOX5 P09917 1/20 0.34
ALDH1A1 P00352 4/20 0.34
HPGD P15428 4/20 0.34
KDM4E B2RXH2 3/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPT P10636 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
GMNN O75496 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852955 1.00 DPP4 (0.42) DPP4CFDTBXAS1PTK2TDP1
SCHEMBL23218847 0.91 CFD (0.43) CFDMEN1KMT2APLGPLAU
SCHEMBL29591552 0.91 CFD (0.43) CFDMEN1KMT2APLGPLAU
SCHEMBL29853086 0.90 CFD (0.41) DPP4CFDTBXAS1ALOX5ALDH1A1
SCHEMBL23218279 0.90 CFD (0.41) DPP4CFDTBXAS1ALOX5ALDH1A1
SCHEMBL23218363 0.87 TBXAS1 (0.37) DPP4CFDTBXAS1PTK2ALOX5
SCHEMBL29852490 0.87 TBXAS1 (0.37) DPP4CFDTBXAS1PTK2ALOX5
SCHEMBL23218624 0.83 ALDH1A1 (0.38) CFDTBXAS1ALOX5ALDH1A1HPGD
SCHEMBL29852653 0.83 ALDH1A1 (0.38) CFDTBXAS1ALOX5ALDH1A1HPGD
SCHEMBL23218652 0.82 CFD (0.43) DPP4CFDTBXAS1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
CN-117120419-A KLK5 bicyclic heteroaromatic inhibitors 拜奥克里斯特制药公司 2023-11-24 CN disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 DPP4 544/4885CFD 3529/4885TBXAS1 2084/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB DPP4 1386/4885CFD 1/4885TBXAS1 963/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB DPP4 1004/4885CFD 1/4885TBXAS1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.